CLINICAL FEATURES AND TREATMENT OUTCOMES OF INFANTS WITH IMMUNE THROMBOCYTOPENIC PURPURA
Abstract number: P-W-309
Arjmandi Rafsanjani1 K.
1Hematology Oncology, Iran University Of Medical Sciences, Tehran, Iran (Islamic Republic of)
How-to-cite Arjmandi Rafsanjani K. CLINICAL FEATURES AND TREATMENT OUTCOMES OF INFANTS WITH IMMUNE THROMBOCYTOPENIC PURPURA. J Thromb Haemost 2007; 5 Supplement 2: P-W-309
Introduction: To determine the clinical features, underlying factors, treatment outcomes of infants with immune thrombocytopenic purpura (ITP).
Methods: Retrospective analysis of 62 infants ITP from 1998 2002, we evaluated age, sex, clinical features, treatment outcomes and the rate of chronic ITP.
Results: Among 62 infant ITP 39 (62.9%) male and 23 (37.1%) female had a median age of 10.8 months
All patients had purpura and 12 (19.5%) of them had active mucosal bleeding most common being epistaxis. In 44 (71%) patients after viral upper respiratory infection, one after chicken pox and 8 (12.9%) after vaccination had ITP. 55 patients received IVIgG, 39 (62.9%) only IVIgG,
16 IVIgG + Prednisoline, 4 only observed and 3 patients received multiple medicine. 46 (74.2%) responded to a single course of treatment, 6 (9.7%) partial and patients no response.
Among our patients 51 (82.25%) had acute ITP and 11 (17.75%) chronic ITP.
Conclusions: Infants with ITP respond favorably to treatment and are less likely to develop chronic ITP, vaccination may play an important role in the etiology of ITP in infants.
The aim of study is to raise awareness of infant ITP.
To cite this abstract use the following format:
Journal of Thrombosis and Haemostasis 2007; Volume 5, Supplement 2: abstract number
||XXIst ISTH Congress
| Back to top